Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
Oger
J
J
Canadian MS Clinics Network, Canada.
Freedman
M
M
D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009462:Neurology / Q000592:standards; D010455:Peptides / Q000627:therapeutic use*
D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta